Midgard Science
V

Viralgen

San Sebastián, Spain viralgen.com From their website, Nov 2026

  • GMP

Work here? Claim this listing

About

Viralgen is an AAV-based gene therapy CDMO that provides end-to-end manufacturing support from construct optimization and plasmid DNA production through clinical and commercial production. It serves biotech and pharmaceutical clients developing gene therapies for rare, ultra-rare, and other genetic diseases from its facilities in San Sebastián, Spain.

Services

  • Process development

    Supports early-stage programs with platform fit, construct optimization, and production strategy, and supports late-stage programs with comparability studies, next-generation process transition, and process characterization/PPQ.

  • AAV manufacturing platform

    Uses the Aava™ platform and Pro10™ cell line to manufacture AAV gene therapies with a high-yield, scalable process.

  • Early phase production

    Produces material for development, toxicology, and Phase I clinical needs from small screening batches through cGMP batches.

  • Late phase production

    Provides manufacturing support for late-stage clinical development and commercialization, including process characterization and PPQ planning.

  • Commercial production

    Provides large-scale AAV manufacturing for commercial supply, including scale-up and scale-out to meet demand.

  • Fill and finish

    Performs fill and finish in dedicated suites with automated isolator-based operations.

  • QC release

    Carries out quality control release work, with much of the QC and CMC work performed in-house.

  • MSAT services

    Supports manufacturing science and technology activities, including process characterization and scale-down studies.

1 more services
  • Plasmid DNA production

Capabilities

Assays and studies
  • AAV
  • Process development
  • Bioreactors
  • HEK293
  • Toxicology
  • Fill-finish
5 more
  • ELISA
  • DNA analysis
  • Physicochemical testing
  • Analytical characterization
  • Process characterization
Scale and capacity
  • 2L screening batches
  • 50L toxicology batches
  • 250L-500L cGMP batches
  • Up to 1,500L per batch
  • Up to 2,000L single-use bioreactors per suite
  • 3 modules
5 more
  • Up to 3 production trains per module
  • 343,000+ square feet
  • 45,000 square feet of clinical-stage infrastructure
  • 300,000+ square feet of commercial readiness
  • 1000m2 MSAT cGMP-like laboratory
Therapeutic areas
  • Gene therapy
  • Rare diseases
  • Ultra-rare diseases
  • Pathway diseases
  • Drug-resistant focal epilepsy
  • Spastic Paraplegia 50
6 more
  • Charcot-Marie-Tooth disease type 4J
  • AADC deficiency
  • NPC
  • NPA
  • Duchenne muscular dystrophy exon 1 deletion
  • MPS IIIC

Instruments and platforms

  • Ambr250 HT system
  • Ultracentrifugation
  • Depth filtration
  • Chromatography skids
  • Tangential flow filtration

Modalities and species

Modalities
  • Viral vector
  • Cell therapy
  • Plasmid DNA
Species and models
  • HEK293-derived cell line
  • Pro10™ suspension cell line

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    Scope: manufacture of human medicinal products, investigational medicinal products and sterile or biological active substances

Details

Type
CDMO
Founded
2017
Team
400+ professionals
Based in
San Sebastián, Spain
Sites
San Sebastián, Spain

Similar labs